Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QCi and INmune Bio partner to study XPro in Alzheimer’s
The initial agreement marks the first commercial contract in the pharmaceutical and biotechnology sector for QCi. Under the first stage of the project, the companies will analyse clinical
The initial agreement marks the first commercial contract in the pharmaceutical and biotechnology sector for QCi. Under the first stage of the project, the companies will analyse clinical
Under the agreement, Alentis has secured an exclusive option to in-license linkers and payloads from PinotBio for use in its pipeline candidates. Financially, PinotBio will receive an upfront
The partnership focuses on biologics quality control as well as viral and release testing under current good manufacturing practice (cGMP) standards. Magellan recently completed Phase I/II clinical studies
Under the partnership, Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets. Pfizer will take full responsibility for subsequent
The company was informed of the decision by its domestic licensing partner, Changchun GeneScience Pharmaceutical (GenSci). GenSci holds exclusive Chinese commercial rights to Camcevi across all existing and
The planned facility will focus on the development, validation, and adoption of new approach methodologies (NAMs). These laboratory, computational, and data-oriented methods are designed to mirror human biology
This oral medication is indicated for patients whose infections do not respond, with or without documented resistance, to standard antiviral therapies including acyclovir, famciclovir, or valacyclovir. The company
Under the terms of the agreement, the two companies will direct qualified customer opportunities to the other across the development pipeline. A joint governance structure will oversee the
The purpose-built 10,000ft² site is fully operational and produces materials to support developers working on cell therapies globally. The facility features two International Organization for Standardization-7 (ISO-7) cleanrooms
The transaction grants Ono exclusive development and commercialisation rights for drug candidates BHV-1300, BHV-1310, and BHV-1320 across the Association of Southeast Asian Nations (ASEAN) countries, Taiwan, South Korea,